Mitochondrial targeting drug lonidamine triggered apoptosis in doxorubicin-resistant HepG2 cells.

[1]  S. Kong,et al.  Concanavalin A induced apoptosis in murine macrophage PU5-1.8 cells through clustering of mitochondria and release of cytochrome c , 2000, Apoptosis.

[2]  A. Szewczyk,et al.  Mitochondria as a Pharmacological Target , 2002, Pharmacological Reviews.

[3]  P. Krammer,et al.  Upregulation of bcl‐2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines , 2002, International journal of cancer.

[4]  Jiandong Chen,et al.  Transcriptional Repression of the Anti-apoptoticsurvivin Gene by Wild Type p53* , 2002, The Journal of Biological Chemistry.

[5]  Scott W. Lowe,et al.  Apoptosis A Link between Cancer Genetics and Chemotherapy , 2002, Cell.

[6]  P. Vandenabeele,et al.  Endonuclease G: a mitochondrial protein released in apoptosis and involved in caspase-independent DNA degradation , 2001, Cell Death and Differentiation.

[7]  X. Wang.  The expanding role of mitochondria in apoptosis. , 2001, Genes & development.

[8]  G. Kroemer,et al.  Adenine nucleotide translocator mediates the mitochondrial membrane permeabilization induced by lonidamine, arsenite and CD437 , 2001, Oncogene.

[9]  S. Gupta,et al.  Molecular steps of death receptor and mitochondrial pathways of apoptosis. , 2001, Life sciences.

[10]  I. Herr,et al.  Cellular stress response and apoptosis in cancer therapy. , 2001, Blood.

[11]  D. Green,et al.  The machinery of programmed cell death. , 2001, Pharmacology & therapeutics.

[12]  K. Vousden,et al.  Regulation and function of the p53 tumor suppressor protein. , 2001, Current opinion in cell biology.

[13]  S. Kong,et al.  Gliotoxin induces apoptosis in cultured macrophages via production of reactive oxygen species and cytochrome c release without mitochondrial depolarization , 2001, Free radical research.

[14]  K. Kinzler,et al.  Role of BAX in the apoptotic response to anticancer agents. , 2000, Science.

[15]  S. Kong,et al.  Reversal of TNF-α resistance by hyperthermia , 2000 .

[16]  Guido Kroemer,et al.  Apoptosis‐inducing factor (AIF): a ubiquitous mitochondrial oxidoreductase involved in apoptosis , 2000, FEBS letters.

[17]  T. Bruno,et al.  Energy metabolism of human LoVo colon carcinoma cells: correlation to drug resistance and influence of lonidamine. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  Guy Makin,et al.  Apoptosis and cancer chemotherapy , 2000, Cell and Tissue Research.

[19]  A. Stavrovskaya.  Cellular mechanisms of multidrug resistance of tumor cells. , 2000, Biochemistry. Biokhimiia.

[20]  G. Kroemer,et al.  Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permeability transition pore , 1999, Oncogene.

[21]  S. Cheng,et al.  Expression of Bcl-2 family proteins during chemotherapeutic agents-induced apoptosis in the hepatoblastoma HepG2 cell line. , 1999, British journal of biomedical science.

[22]  S. Lowe,et al.  Clinical implications of p53 mutations , 1999, Cellular and Molecular Life Sciences CMLS.

[23]  G. Kroemer,et al.  Mitochondria in chemotherapy-induced apoptosis: a prospective novel target of cancer therapy (review). , 1998, International journal of oncology.

[24]  G. Kroemer,et al.  The mitochondrial death/life regulator in apoptosis and necrosis. , 1998, Annual review of physiology.

[25]  C. Franceschi,et al.  JC‐1, but not DiOC6(3) or rhodamine 123, is a reliable fluorescent probe to assess ΔΨ changes in intact cells: implications for studies on mitochondrial functionality during apoptosis , 1997, FEBS letters.

[26]  G R Nakayama,et al.  Assessment of the Alamar Blue assay for cellular growth and viability in vitro. , 1997, Journal of immunological methods.

[27]  V. Ling.  Multidrug resistance: molecular mechanisms and clinical relevance , 1997, Cancer Chemotherapy and Pharmacology.

[28]  O. Fardel,et al.  The P-glycoprotein multidrug transporter. , 1996, General pharmacology.

[29]  C Haanen,et al.  A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. , 1995, Journal of immunological methods.

[30]  G. Navon,et al.  Mechanism of action of the antineoplastic drug lonidamine: 31P and 13C nuclear magnetic resonance studies. , 1995, Cancer research.

[31]  G. Kroemer,et al.  Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo , 1995, The Journal of experimental medicine.

[32]  D. Fisher.  Apoptosis in cancer therapy: Crossing the threshold , 1994, Cell.

[33]  G. Kruh,et al.  Doxorubicin and multidrug resistance , 1993, Current opinion in oncology.

[34]  I. Pastan,et al.  Fluorescent cellular indicators are extruded by the multidrug resistance protein. , 1993, The Journal of biological chemistry.

[35]  I. Pastan,et al.  Biochemistry of multidrug resistance mediated by the multidrug transporter. , 1993, Annual review of biochemistry.

[36]  P. Mosesso,et al.  Lonidamine: a non-mutagenic antitumor agent. , 1990, Carcinogenesis.

[37]  B. Silvestrini,et al.  Lonidamine and related compounds. , 1984, Progress in medicinal chemistry.